更新大流行H1N1株的俄骨架减毒流感疫苗对冈比亚儿童排毒与免疫原性的影响
该开放标签4期观察性研究在冈比亚24-59月龄儿童中比较含Cal09或NY15 pH1N1株的俄骨架三价LAIV,发现NY15株显著提高第2天鼻咽排毒率、血清阳转率及CD4+ T细胞反应,持续排毒至第7天与免疫应答独立相关。
要点
- 更新pH1N1株可改善LAIV在儿童中的复制适应性和免疫原性。
- 持续排毒至第7天与血清阳转和CD4+ T细胞反应独立相关。
- 选择年度LAIV组分时需评估复制适应性而不仅是抗原性。
核心结论
- 2016至2018年间更换pH1N1组分可能克服了既往LAIV的低效价。
- NY15株较Cal09株显著提高排毒、血清阳转和T细胞反应。
研究设计与样本
- 开放标签、前瞻性、观察性4期研究,嵌套于随机对照试验NCT02972957。
- 2016-17年入组118名儿童接种Cal09 LAIV,2017-18年入组135名儿童接种NY15 LAIV(126名完成)。
- 纳入24-59月龄临床健康儿童,接种单剂WHO预认证俄骨架三价LAIV。
临床怎么用
- 选择LAIV年度株时应评估复制适应性,而不仅依赖抗原性匹配。
- 对基线血清阴性儿童,更新pH1N1株可能带来更大免疫益处。
局限性
- 开放标签、观察性设计,非随机对照比较Cal09与NY15。
- 单中心、 periurban地区儿童,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy and effectiveness of the pandemic H1N1 (pH1N1) component in live attenuated influenza vaccine (LAIV) is poor. The reasons for this paucity are unclear but could be due to impaired replicative fitness of pH1N1 A/California/07/2009-like (Cal09) strains. We assessed whether an updated pH1N1 strain in the Russian-backbone trivalent LAIV resulted in greater shedding and immunogenicity compared with LAIV with Cal09. METHODS: We did an open-label, prospective, observational, phase 4 study in Sukuta, a periurban area in The Gambia. We enrolled children aged 24-59 months who were clinically well. Children received one dose of the WHO prequalified Russian-backbone trivalent LAIV containing either A/17/California/2009/38 (Cal09) or A/17/New York/15/5364 (NY15) based on their year of enrolment. Primary outcomes were the percentage of children with LAIV strain shedding at day 2 and day 7, haemagglutinin inhibition seroconversion, and an increase in influenza haemagglutinin-specific IgA and T-cell responses at day 21 after LAIV. This study is nested within a randomised controlled trial investigating LAIV-microbiome interactions (NCT02972957). FINDINGS: Between Feb 8, 2017, and April 12, 2017, 118 children were enrolled and received one dose of the Cal09 LAIV from 2016-17. Between Jan 15, 2018, and March 28, 2018, a separate cohort of 135 children were enrolled and received one dose of the NY15 LAIV from 2017-18, of whom 126 children completed the study. Cal09 showed impaired pH1N1 nasopharyngeal shedding (16 of 118 children [14%, 95% CI 8·0-21·1] with shedding at day 2 after administration of LAIV) compared with H3N2 (54 of 118 [46%, 36·6-55·2]; p<0·0001) and influenza B (95 of 118 [81%, 72·2-87·2]; p<0·0001), along with suboptimal serum antibody (seroconversion in six of 118 [5%, 1·9-10·7]) and T-cell responses (CD4+ interferon γ-positive and/or CD4+ interleukin 2-positive responses in 45 of 111 [41%, 31·3-50·3]). After the switch to NY15, a significant increase in pH1N1 shedding was seen (80 of 126 children [63%, 95% CI 54·4-71·9]; p<0·0001 compared with Cal09), along with improvements in seroconversion (24 of 126 [19%, 13·2-26·8]; p=0·011) and influenza-specific CD4+ T-cell responses (73 of 111 [66%, 60·0-75·6; p=0·00028]). The improvement in pH1N1 seroconversion with NY15 was even greater in children who were seronegative at baseline (24 of 64 children [38%, 95% CI 26·7-49·8] vs six of 79 children with Cal09 [8%, 2·8-15·8]; p<0·0001). Persistent shedding to day 7 was independently associated with both seroconversion (odds ratio 12·69, 95% CI 4·1-43·6; p<0·0001) and CD4+ T-cell responses (odds ratio 7·83, 95% CI 2·99-23·5; p<0·0001) by multivariable logistic regression. INTERPRETATION: The pH1N1 component switch that took place between 2016 and 2018 might have overcome the poor efficacy and effectiveness reported with previous LAIV formulations. LAIV effectiveness against pH1N1 should, therefore, improve in upcoming influenza seasons. Our data highlight the importance of assessing replicative fitness, in addition to antigenicity, when selecting annual LAIV components. FUNDING: The Wellcome Trust.
引用
- Lindsey BB, Jagne YJ, Armitage EP, et al. Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study. Lancet Respir Med. 2019. PMID: 31235405. doi:10.1016/S2213-2600(19)30086-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。